Home Title Index Topic Index Sources Directory News Releases Sources Calendar

Anavex Receives Approval to Commence Phase I Clinical Trial in Alzheimer's Disease
Sources News Release

http://www.sources.com/Releases/NR1208.htm

Publisher:  Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot
Date Written:  21/03/2011
Year Published:  2011  
Resource Type:  Article

Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) has announced that its clinical trial application (CTA) for ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease, has been approved by the German regulatory health authority, BfArM. The

Abstract:  ANAVEX 2-73 trial to be initiated immediately in Germany

Hoboken, NJ – March 15, 2011 -- Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced that its clinical trial application (CTA) for ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease, has been approved by the German regulatory health authority, BfArM. The Phase I trial of ANAVEX 2-73, which includes testing in healthy human volunteers, will commence immediately. In this Phase...
To read the full release go to http://www.sources.com/Releases/NR1208.htm

Topics


Sources-journalists use the sources website to find you


AlterLinks
c/o Sources


© 2023.